RESIST-TB released its July 2022 newsletter with the latest research publications on drug-resistant TB.

Wealthy nations, including the United States, have treated the Covid-19 pandemic as a once-in-a-century threat to public health that necessitated an unprecedented response, both in sped-up vaccine development and counter-measures like lockdowns.

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) will conduct a three half-days conference Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines on 16-18 August 2022.

The vaccine candidate VPM1002 shows its safety in a study with HIV- and non-HIV-exposed newborns.

An all-oral treatment regimen for multidrug-resistant tuberculosis (MDR-TB) recently recommended as a new standard of care by the World Health Organization is effective and safe in people living with HIV, Dr Ilaria Motta of Médecins sans Frontières reported at the 24th International AIDS Conference (AIDS 2022) in Montreal.

At the International AIDS Conference in Montreal, civil society and activist organizations launched a new campaign inspired by the legacy of the late Dr. Paul Farmer calling for the “staff, stuff, space, systems, and support” necessary for shorter, effective TB treatment regimens to reach all who need them as a human right by the end of 2024.

Partners announce two new agreements to lower the price of rifapentine-based treatments to prevent TB in low- and middle-income countries.

MONTREAL, 31 July 2022 – A new report [ download in English | Español | Français | Русский ] released by the Global Fund today at the 24th International AIDS Conference unveils key findings of the activities supported by the Global Fund’s Breaking Down Barriers initiative, a groundbreaking program launched in 2017 to provide intensive financial and technical support to 20 countries* to address stigma and discrimination, criminalization and other human rights-related obstacles that continue to threaten progress against HIV, tuberculosis (TB), and malaria.

A large campaign in Uganda to ramp up HIV testing and immediate HIV treatment reduced the incidence of tuberculosis (TB) in the intervention communities by 27% after one year, underlining the potential impact of HIV-related investments on wider population health, investigators of the SEARCH study reported at the 24th International AIDS Conference (AIDS 2022).

The TB Europe Coalition released a brochure aiming to inform the National TB Programs, civil society organizations, TB-affected community, and stakeholders about the three assessment tools in the field of TB developed by the Stop TB Partnership in relation to TB stigma, gender-related and service-related barriers.